SUMMARY Cardiac size and function was studied in 23 acromegalic patients using echocardiography and systolic time interval measurements. Thirteen patients (56%) had increased left ventricular mass, and in the 20 treated patients this correlated well with the mean of the recent basal growth hormone levels. It is suggested that myocardial hypertrophy may regress in proportion to the degree of control of growth hormone levels. The ejection fraction was normal in all patients except one, and increased left ventricular mass was not associated with detectable impairment of left ventricular performance. Thus, most acromegalic hearts function normally even when their mass is considerably increased, though the longterm effects of this are unknown. Echocardiography will be valuable in the serial monitoring of the cardiac effects of acromegaly.
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Cardiac enlargement has been known to be a feature of acromegaly since the end of the last century (Huchard, 1895) , and an increase in overall cardiac mass, occasionally to an extreme degree, is typically found at necropsy (Courville and Mason, 1938; Hejtmancik et al., 1951) . Heart failure is an uncommon but well-recognised complication, and may occur even in the absence of associated hypertension or ischaemic heart disease (Courville and Mason, 1938; Pepine and Aloia, 1970) . It might be expected that the increase in cardiac mass leads to impaired performance, but there is little documented evidence to support this, nor is it established whether the myocardial hypertrophy is reversible after treatment of acromegaly. We have, therefore, studied a group of acromegalic patients, using echocardiographic recordings and systolic time interval data to estimate both left ventricular mass and performance, in order to investigate the relation between these two indices, and to consider the possible effects of treatment on left ventricular mass.
Patients (see Table 1) Studies were made on 23 patients in whom a diagnosis of acromegaly had been made from the clinical features and demonstration of a resting, fasting growth hormone (GH) level exceeding 10 mU/l which was not suppressed by a 50 g oral glucose load. There were 12 men and 11 women, with ages Received for publication 30 October 1978 ranging from 24 to 80 years (mean age 46 years). The estimated duration of the disease ranged from 1 to 30 years. Thirteen patients had been treated by hypophysectomy (with or without external radiotherapy), 7 patients had been treated conservatively by external radiotherapy only, and 3 patients were untreated. Nine patients were receiving hydrocortisone and thyroxine replacement therapy. Eighteen patients had normal GH levels at the time of the study, and in 15 of these the levels had remained within the normal range for at least 1 year. Four patients (cases 5, 8, 10, and 23) (Hartog and Wright, 1969) (1) The left ventricular internal diameter, both at end-diastole (LVD) and at end-systole (LVS).
(2) The interventricular septal thickness (ST) at end-diastole. (3) The left posterior wall thickness (PWT) (the distance between the endocardial and epicardial echoes at end-diastole). Measurement from the anterior edges of these echoes gives a smaller normal range than that usually quoted (Feigenbaum, 1976) but is theoretically more valid (Roelandt, 1977) and has produced a range of left ventricular mass in 20 normal subjects of 80 to 200 g (mean 140 g); this corresponds well to that of 91 to 203 g (mean 135 g) reported from necropsy examination of normal hearts (Reiner et al., 1959 These were made from simultaneous recordings of high frequency phonocardiograms, carotid pulse (using a hand-held funnel pick-up, air-coupled to a crystal transducer), and the standard electrocardiographic lead which showed the earliest onset of the QRS complex, using the Cambridge recorder on photographic paper at 200 mm/s. Values for the pre-ejection period (PEP), left ventricular ejection time (LVET), and hence the PEP/LVET ratio were derived according to the method described by Weissler and Garrard (1971) , again without knowledge of the clinical details of the patient concerned.
Results (see Table 2) LEFT VENTRICULAR MASS (LVM) Thirteen patients (56%) showed increased left ventricular mass, which exceeded 300 g in 5 patients, and in 3 of these (cases 9, 13, and 17) was more than 400 g. In general the left ventricular found a close relation between the left ventricular mass and the mean value of the basal GH levels during the year before the study in the 20 treated patients (Fig.) . The left ventricular mass was normal or only moderately raised in the 15 patients whose GH levels had been well controlled for at least 1 year, whereas it was clearly greater in 4 of the 5 patients in whom the treatment had been unsuccessful, or in whom reduction of GH levels was very recent; only 1 of these 4 patients had associated hypertension. Though echocardiography was not performed before treatment, this relation suggests that the myocardial hypertrophy of acromegaly may regress after treatment in proportion to the degree of control of GH levels. However, serial studies on these patients are needed to confirm this.
One of the 3 untreated patients (case 13) had very (Feigenbaum et al., 197 1972) , provided that there is ni motion abnormality (Feigenbaur of pre-ejection period (PEP) t ejection time (LVET) has bee increased in subjects with heart et al., 1968) and has also been u; left ventricular performance. Onl3 in our series of 23 acromegalic subjects was found to have an abnormally small ejection fraction, and this patient also had the highest PEP/LVET ratio; she was atypical in that her acromegaly was superimposed on long-standing Addison's disease but, since she had been receiving apparently adequate adrenocortical hormone replacement therapy for many years, the contribution of this additional factor was difficult to assess. In the other 22 patients the ejection fraction was normal. Three of these other patients had an abnormally high PEP/LVET ratio (in each case resulting from a prolonged preejection period) but in 2 this can be attributed to 400 500 600 other factors, namely the previous myocardial infarction of case 20 (Weissler and Garrard, 1971) , ular mass and and the advanced age of case 23 (Harrison et al., reated acromegalic 1964) . The explanation in case 22 is obscure, but the reliability of systolic time interval criteria in the individual subject has been questioned since ndingly high left falsely positive and negative values are not unther 2 untreated common (Braunwald et al., 1976) , and there is now t ventricular mass considerable evidence favouring ejection fraction as levels. However, the best overall index of basal left ventricular recent onset, and function (Braunwald et al., 1976 ). Thus we found Addison's disease. convincing evidence of subclinical impairment of musual in that the myocardial performance in only 1 patient (case 7); aly had remained further, there was no correlation between the left ventricular mass and either the ejection fraction If the patients with or the PEP/LVET ratio. entric increase in It does not, therefore, seem that increasing myosmall number of cardial hypertrophy leads to impaired function, and disproportionately indeed most acromegalic hearts appear to function perience of others well, regardless of size. This is in agreement with t al., 1976). The other reports (Bodem et al., 1976; Martins et al., earne et al., 1975 Martins et al., earne et al., ) 1977 . Our study does not support the findings of a i almost all acro-report on 10 acromegalic patients, in which a high ic feature, was not incidence of subclinical muscle disease was suggestrecognised that a ed on the basis of systolic time interval measureventricular hyper-ments alone (Jonas et al., 1975) . However, the PEP/ is aortic stenosis) LVET ratio was strikingly abnormal in only 2 thickening (Maron patients in the above report, 1 of whom had preacromegalic hearts viously had a myocardial infarction; in the other patients the abnormal ratios were largely the result r ejection fraction of a shortened left ventricular ejection time with ance is well estab-a normal pre-ejection period, which is not the xists between the pattern that theoretical considerations would predict 1 from echocardio-in subclinical myocardial disease. The low incidence obtained by angio-of subclinical myocardial impairment in our acro-2; Murray et al., megalic patients contrasts with the high prevalence Lo segmental wall of overt cardiac failure described in earlier reports 1, 1976). The ratio (Courville and Mason, 1938; HejtmLancik et al., o left ventricular 1951) . It is possible that this represents a true fall :n shown to be in the incidence of myocardial dysfunction, related failure (Weissler in part to earlier and more effective definitive sed as an index of treatment. y 1 patient (case 7)
In conclusion, we found that considerable myo-cardial hypertrophy in treated patients was only present when control of growth hormone levels was inadequate, suggesting that the former may be at least partially reversible after effective treatment. There was no evident correlation between myocardial hypertrophy and performance, and indeed the latter was normal in all patients except one. Nevertheless, the long-term functional effects of the hypertrophy, persisting over decades, remain unclear.
The serial use of echocardiography in individual patients promises to be of importance in assessing the effect of treatment in preventing potentially serious alterations of heart size and function in acromegaly.
